Adults 60 to 90, any sex, with Suspected Typical Alzheimer's Disease (AD) or Suspected Atypical Alzheimer's Disease (AD). Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Agreement of Cognitive Test Results Across Testing Modalities as Measured by Neuropsychological Test Mean Scores, Measures With Total Correct ItemsPrimary· After the exposure to each health delivery conditions, Face-to-face evaluation (FF) and TeleNP evaluation, at Week 1 and Weeks 5-7
Raw scores for measures of Memory, Executive Functions, Language, and Spatial Abilities will be compared across both conditions.
CVLT= California Verbal Learning Test- 2nd edition; Delayed recall measures Memory, total words recalled after 20-minutes (range: 0-16). Higher=better.
RBANS = Repeatable Battery for the Assessment of Neuropsychological Status; Delayed recall (Memory) - total elements recalled (range: 0-20). Higher=better.
Figure Copy (Spatial)- total copied (range: 0-20). BNT=Boston Naming Test (Language) -total correct (range: 0-15). Higher=better. Category Fluency (Language) -
CVLT Delayed Recall (Memory). Total Score, Higher=better score.
Group
Value
95% CI
Teleneuropsychology (TeleNP)
4.31
± 4.30
Face-to-Face (FF)
4.40
± 4.20
RBANS Figure Delayed Recall (Memory). Total Score, Higher=better score.
Group
Value
95% CI
Teleneuropsychology (TeleNP)
8.21
± 5.20
Face-to-Face (FF)
8.60
± 4.90
BNT-15 item Total (Language), Total Score, Higher=better score.
Group
Value
95% CI
Teleneuropsychology (TeleNP)
12.40
± 3.20
Face-to-Face (FF)
12.52
± 3.20
Category Fluency Total (Language), Total Score, Higher=better score.
Group
Value
95% CI
Teleneuropsychology (TeleNP)
13.19
± 5.50
Face-to-Face (FF)
12.83
± 5.80
JoLO 15-item Total (Spatial), Total Score, Higher=better score.
Group
Value
95% CI
Teleneuropsychology (TeleNP)
10.60
± 3.40
Face-to-Face (FF)
11.10
± 3.00
RBANS Figure Copy (Spatial), Total Score, Higher=better score.
Group
Value
95% CI
Teleneuropsychology (TeleNP)
17.08
± 2.50
Face-to-Face (FF)
17.21
± 2.60
Agreement of Neuropsychologist Diagnosis Across Testing Modalities as Measured by Neuropsychologist-Determined DiagnosisPrimary· After the exposure to each health delivery conditions, Face-to-face evaluation (FF) and TeleNP evaluation, at Week 1 and Weeks 5-7
Neuropsychologist-determined diagnosis (i.e., typical AD, atypical/complex AD, not AD) will be compared across both conditions whether TeleNP alters assessment of patient diagnosis.
Group
Value
95% CI
Syndrome Across Modalities
0.74
0.60 – 0.88
Agreement of Neuropsychologist Appraisal of Severity Across Testing Modalities as Measured by Neuropsychologist-Determined SeverityPrimary· After the exposure to each health delivery conditions, Face-to-face evaluation (FF) and TeleNP evaluation, at Week 1 and Weeks 5-7
Neuropsychologist-determined severity (i.e., subjective cognitive concerns; MCI; mild dementia) will be compared across both conditions whether TeleNP alters assessment of patient severity.
Group
Value
95% CI
Severity Across Modalities
0.89
0.79 – 0.99
Acceptability and Feasibility of Intervention Measures as Measured by 4-item Acceptability and Feasibility of Intervention Measures ScalePrimary· After the exposure to each health delivery conditions, Face-to-face evaluation (FF) and TeleNP evaluation, at Week 1 and Weeks 5-7
The 4-item Acceptability and Feasibility of Intervention Measures Scale is used for rating all participants and care partners' perspective on the acceptability and feasibility of the Face-to-face evaluation (FF) and TeleNP evaluation as assessed using a 5-point Likert scale at Week 1 or Weeks 5-7, depending on randomization. Scores range from "Completely disagree" (1) to "Completely agree" (5).
TeleNP. Acceptability of Intervention Measure. Range 1-5; Higher=More Acceptable
Group
Value
95% CI
Patient (Acceptability Measure)
4.0
3.5 – 4.5
Care Partner (Acceptability Measure)
3.95
3.3 – 4.8
TeleNP. Intervention Appropriateness Measure. Range 1-5; Higher=More Acceptable
Group
Value
95% CI
Patient (Acceptability Measure)
4.0
3.5 – 4.3
Care Partner (Acceptability Measure)
4.0
3.5 – 4.5
TeleNP. Feasibility of Intervention Measure. Range 1-5; Higher=More Acceptable
Group
Value
95% CI
Patient (Acceptability Measure)
4.0
3.8 – 4.5
Care Partner (Acceptability Measure)
4.0
3.8 – 4.8
FF (Face-to-Face). Acceptability of Intervention Measure. Range 1-5; Higher=More Acceptable
Group
Value
95% CI
Patient (Acceptability Measure)
4.0
3.5 – 5.0
Care Partner (Acceptability Measure)
3.9
3.5 – 4.3
FF (Face-to-Face). Intervention Appropriateness Measure. Range 1-5; Higher=More Acceptable
Group
Value
95% CI
Patient (Acceptability Measure)
4.0
4.0 – 4.8
Care Partner (Acceptability Measure)
4.0
4.0 – 4.8
FF (Face-to-Face). Feasibility of Intervention Measure. Range 1-5; Higher=More Acceptable
Group
Value
95% CI
Patient (Acceptability Measure)
4.0
3.8 – 4.8
Care Partner (Acceptability Measure)
4.0
3.8 – 4.8
Acceptability and Feasibility of Intervention Measures as Measured by 19-item UTAUT Questionnaire Adapted to TeleNPPrimary· After the exposure to the TeleNP evaluation (up to Week 7)
The UTAUT questionnaire adapted to TeleNP is used for rating all participants' perspective on the acceptability and feasibility of TeleNP evaluation as assessed using a 5-point Likert scale at Week 1 or Weeks 5-7, depending on randomization. Scores range from "Strongly disagree" (1) to "Strongly agree" (5).
Performance expectancy refers to the degree to which an individual believes that using a technology will help them improve their performance.
Effort expectancy is the degree of ease associated with using the technology. Behavioral intention reflects an individual's plan to use the technol
Performance Expectancy Domain
Group
Value
95% CI
Patient (UTAUT Measure)
4.0
3.0 – 5.0
Effort Expectancy Domain
Group
Value
95% CI
Patient (UTAUT Measure)
4.0
3.0 – 4.0
Behavioral Intention Domain
Group
Value
95% CI
Patient (UTAUT Measure)
4.0
3.0 – 4.0
Agreement of Cognitive Test Results Across Testing Modalities as Measured by Neuropsychological Test Mean Scores (Timed Measures)Primary· After the exposure to each health delivery conditions, Face-to-face evaluation (FF) and TeleNP evaluation, at Week 1 and Weeks 5-7
Raw scores for measures of Executive Functions will be compared across both conditions.
DKEFS= Delis-Kaplan Executive Function Systems; Color-Word Inhibition (Executive Functions) -total time (range: 0-180"). Higher=worse Oral Trail Making Test B (Executive Functions) total time (range: 0-300"). Higher=worse
DKEFS Color-Word Inhibition Total Time
Group
Value
95% CI
Teleneuropsychology (TeleNP)
104.84
± 44.10
Face-to-Face (FF)
96.29
± 38.10
Oral Trail Making Test, Total Time
Group
Value
95% CI
Teleneuropsychology (TeleNP)
88.54
± 87.10
Face-to-Face (FF)
79.59
± 83.30
Sponsor's own description
The overarching goal of this study is to a) assess the feasibility and preliminary validity of home-based delivery of TeleNP to patients with suspected Alzheimer's Disease (AD), referred for cognitive assessments in a Neurology Clinic; and b) elucidate whether TeleNP is equivalent to face-to-face evaluation (FF) for diagnostic adjudication of atypical versus typical AD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Colorado, Denver
Last refreshed: 31 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05379023.